MarketInOut Stock Screener Log In | Sign Up
 

LENZ Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026
LENZ Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization97.25 mln
Float27.17 mln
Earnings Date10/29/2026

Piotroski F-Score

3 / 9
Below average

Beneish M-Score

0.05
Highly suspicious

1-Year Forecast

20.00
Transformational upside

Relative Strength

19 / 100
Significantly lagging

Debt / Equity

0.00
Debt-free

Pre-Tax Margin

-587%
Severely loss-making

Business Description

LENZ Therapeutics is a US-based pharmaceutical company dedicated to helping adults see more clearly as they age. Founded in 2013 and based in Solana Beach, California, the company is working to bring new eye drop treatments to market that address presbyopia, the gradual loss of near vision that affects most people in middle age. Its leading treatments, VIZZ and LNZ101, are designed to offer patients a practical alternative to reading glasses.

Key Fundamentals

EPS-4.13
ROE-54.77
RPS0.70
ROIC-1,482
ROA-50.68
EBITDA, mln-126
EV / EBITDA0.79
EV / EBIT0.79
Revenue, mln21.48

Quote Details

Last 3.16
Change -0.09 (-2.77%)
Open 3.23
Volume 696,418
Turnover 2,200,681
Average Volume 766,009

Financial Ratios

Pre-Tax Profit Margin-587
Leverage Ratio1.08
Current Ratio13.55
Price / Book0.55
Price / Tangible Book0.55
Debt / Equity0.00
Price / Sales5.30

Financial Strength

Altman Z-Score1.85
Piotroski F-Score 3 / 9
Beneish M-Score0.05
1-Year Target Price20.00
Short Ratio13.99
Short % of Float55.29

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -3.36% 21 / 100   
1 Month -15.05% 23 / 100   
2 Months -36.29% 13 / 100   
6 Months -66.31% 7 / 100   
1 Year -90.34% 5 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog